# TEVA catalysts: TEVA PHARMACEUTICAL INDUSTRIES LTD PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/teva/catalysts

> TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has 9 upcoming catalysts. The next is the TEV-56248 topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | TEVA PHARMACEUTICAL INDUSTRIES LTD |
| Ticker | TEVA (NYSE) |
| SEC CIK | 818686 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/teva |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 28, 2011 | [Milprosa (progesterone) complete response letter (CRL)](https://sec-api.dev/pdufa/progesterone) | TEVA |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22201110_2020_Orig1s000OtherActionLtrs.pdf%22)) |
| March 23, 2016 | [Cinqair (reslizumab) FDA approval](https://sec-api.dev/pdufa/reslizumab) | TEVA |  | completed, approved | "BLA761033 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20160323, review_priority STANDARD; sponsor_name TEVA RESPIRATORY LLC; product CINQAIR (RESLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761033%22)) |
| May 27, 2016 | [AUSTEDO (deutetrabenazine) complete response letter (CRL)](https://sec-api.dev/pdufa/deutetrabenazine) | TEVA |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA208082_20160527.pdf%22)) |
| June 1, 2016 | [Romidepsin (romidepsin) complete response letter (CRL)](https://sec-api.dev/pdufa/romidepsin) | TEVA |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22208574Orig1s000%2COrig2s000OtherActionLtrs.pdf%22)) |
| September 30, 2016 | [Cassipa (buprenorphine hydrochloride; naloxone hydrochloride) complete response letter (CRL)](https://sec-api.dev/pdufa/buprenorphine-naloxone) | TEVA |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22208042_2018_Orig1s000OtherActionLtrs.pdf%22)) |
| January 17, 2017 | [Vantrela Er (hydrocodone bitartrate) FDA approval](https://sec-api.dev/pdufa/hydrocodone) | TEVA |  | completed, approved | "NDA207975 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20170117, review_priority STANDARD; sponsor_name TEVA BRANDED PHARM; product VANTRELA ER (HYDROCODONE BITARTRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207975%22)) |
| January 27, 2017 | [Armonair Respiclick (fluticasone propionate) FDA approval](https://sec-api.dev/pdufa/fluticasone-propionate) | TEVA |  | completed, approved | "NDA208798 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20170127, review_priority STANDARD; sponsor_name TEVA PHARM; product ARMONAIR RESPICLICK (FLUTICASONE PROPIONATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208798%22)) |
| January 27, 2017 | [Airduo Digihaler (fluticasone propionate; salmeterol xinafoate) FDA approval](https://sec-api.dev/pdufa/fluticasone-propionate-salmeterol-xinafoate) | TEVA |  | completed, approved | "NDA208799 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20170127, review_priority STANDARD; sponsor_name TEVA PHARM; product AIRDUO DIGIHALER (FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208799%22)) |
| April 3, 2017 | [AUSTEDO (deutetrabenazine) FDA approval](https://sec-api.dev/pdufa/deutetrabenazine) | TEVA |  | completed, approved | "NDA208082 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170403, review_priority STANDARD; sponsor_name TEVA BRANDED PHARM; product AUSTEDO (DEUTETRABENAZINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208082%22)) |
| June 2, 2017 | [Romidepsin (romidepsin) complete response letter (CRL)](https://sec-api.dev/pdufa/romidepsin) | TEVA |  | completed, complete response letter | "We have completed our review of this application, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22208574Orig1s000%2COrig2s000OtherActionLtrs.pdf%22)) |
| August 30, 2017 | [AUSTEDO (deutetrabenazine) FDA approval](https://sec-api.dev/pdufa/deutetrabenazine) | TEVA |  | completed, approved | "NDA209885 ORIG-1 (Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval): submission_status AP, submission_status_date 20170830, review_priority PRIORITY; sponsor_name TEVA BRANDED PHARM; product AUSTEDO (DEUTETRABENAZINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209885%22)) |
| October 26, 2017 | [Faslodex (fulvestrant) complete response letter (CRL)](https://sec-api.dev/pdufa/fulvestrant) | TEVA |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22210063_2019_Orig1s000OtherActionLtrs.pdf%22)) |
| September 7, 2018 | [Cassipa (buprenorphine hydrochloride; naloxone hydrochloride) FDA approval](https://sec-api.dev/pdufa/buprenorphine-naloxone) | TEVA |  | completed, approved | "NDA208042 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20180907, review_priority STANDARD; sponsor_name TEVA PHARMS USA; product CASSIPA (BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208042%22)) |
| September 14, 2018 | [Ajovy (fremanezumab-vfrm) FDA approval](https://sec-api.dev/pdufa/fremanezumab-vfrm) | TEVA |  | completed, approved | "BLA761089 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180914, review_priority PRIORITY; sponsor_name TEVA PHARMS USA; product AJOVY (FREMANEZUMAB-VFRM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761089%22)) |
| September 5, 2019 | [Fosaprepitant Dimeglumine (fosaprepitant dimeglumine) FDA approval](https://sec-api.dev/pdufa/fosaprepitant-dimeglumine) | TEVA |  | completed, approved | "NDA210064 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20190905, review_priority STANDARD; sponsor_name TEVA PHARMS USA; product FOSAPREPITANT DIMEGLUMINE (FOSAPREPITANT DIMEGLUMINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210064%22)) |
| January 27, 2020 | [Ajovy (fremanezumab-vfrm) label expansion decision](https://sec-api.dev/pdufa/fremanezumab-vfrm) | TEVA |  | completed, approved | "BLA761089 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20200127, review_priority STANDARD; sponsor_name TEVA PHARMS USA; product AJOVY (FREMANEZUMAB-VFRM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761089%22)) |
| March 13, 2020 | [Romidepsin (romidepsin) FDA approval](https://sec-api.dev/pdufa/romidepsin) | TEVA |  | completed, approved | "NDA208574 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20200313, review_priority STANDARD; sponsor_name TEVA PHARMS USA INC; product ROMIDEPSIN (ROMIDEPSIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208574%22)) |
| June 24, 2021 | [AUSTEDO (deutetrabenazine) label expansion decision](https://sec-api.dev/pdufa/deutetrabenazine) | TEVA |  | completed, approved | "NDA208082 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20210624, review_priority PRIORITY; sponsor_name TEVA BRANDED PHARM; product AUSTEDO (DEUTETRABENAZINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208082%22)) |
| July 9, 2021 | [Armonair Respiclick (fluticasone propionate) label expansion decision](https://sec-api.dev/pdufa/fluticasone-propionate) | TEVA |  | completed, approved | "NDA208798 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20210709, review_priority PRIORITY; sponsor_name TEVA PHARM; product ARMONAIR RESPICLICK (FLUTICASONE PROPIONATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208798%22)) |
| July 9, 2021 | [Airduo Digihaler (fluticasone propionate; salmeterol xinafoate) label expansion decision](https://sec-api.dev/pdufa/fluticasone-propionate-salmeterol-xinafoate) | TEVA |  | completed, approved | "NDA208799 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20210709, review_priority STANDARD; sponsor_name TEVA PHARM; product AIRDUO DIGIHALER (FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208799%22)) |
| July 30, 2021 | [Micafungin In Sodium Chloride 0.9% (micafungin sodium) FDA approval](https://sec-api.dev/pdufa/micafungin) | TEVA |  | completed, approved | "NDA212125 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20210730, review_priority STANDARD; sponsor_name TEVA PHARMS USA INC; product MICAFUNGIN (MICAFUNGIN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212125%22)) |
| April 15, 2022 | [UZEDY (risperidone) complete response letter (CRL)](https://sec-api.dev/pdufa/risperidone) | TEVA |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22213586_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| February 17, 2023 | [AUSTEDO (deutetrabenazine) FDA approval](https://sec-api.dev/pdufa/deutetrabenazine) | TEVA |  | completed, approved | "AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| April 28, 2023 | [UZEDY (risperidone) FDA approval](https://sec-api.dev/pdufa/risperidone) | TEVA | schizophrenia in adults | completed, approved | "UZEDY (risperidone) extended-release injectable suspension was approved by the FDA on April 28, 2023 for the treatment of schizophrenia in adults, and was launched in the U.S. in May 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| May 11, 2023 | [TAXOL® (paclitaxel) FDA approval](https://sec-api.dev/pdufa/paclitaxel) | TEVA |  | completed, approved | "NDA216338 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230511, review_priority STANDARD; sponsor_name TEVA PHARMS INC; product PACLITAXEL (PACLITAXEL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216338%22)) |
| November 21, 2023 | [TAXOL® (paclitaxel) label expansion decision](https://sec-api.dev/pdufa/paclitaxel) | TEVA |  | completed, approved | "NDA216338 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20231121, review_priority STANDARD; sponsor_name TEVA PHARMS INC; product PACLITAXEL (PACLITAXEL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216338%22)) |
| November 29, 2023 | [Alvaiz (eltrombopag choline) FDA approval](https://sec-api.dev/pdufa/eltrombopag-choline) | TEVA |  | completed, approved | "NDA216774 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20231129, review_priority STANDARD; sponsor_name TEVA PHARMS INC; product ALVAIZ (ELTROMBOPAG CHOLINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216774%22)) |
| February 24, 2024 | [SIMLANDI® (simlandi) FDA approval](https://sec-api.dev/pdufa/simlandi) | TEVA |  | completed, approved | "On February 24, 2024, Alvotech and Teva announced that the FDA approved SIMLANDI" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| February 24, 2024 | [AMJEVITA® (adalimumab) FDA approval](https://sec-api.dev/pdufa/adalimumab) | TEVA |  | completed, approved | "On February 24, 2024, Alvotech and Teva announced that the FDA approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira®, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn's disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/exh_991.htm)) |
| April 16, 2024 | [WEZLANA® (ustekinumab) FDA approval](https://sec-api.dev/pdufa/ustekinumab) | TEVA |  | completed, approved | "On April 16, 2024, Alvotech and Teva announced that the FDA has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients six years and older." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/exh_991.htm)) |
| May 2024 | [AUSTEDO (deutetrabenazine) FDA approval](https://sec-api.dev/pdufa/deutetrabenazine) | TEVA |  | completed, approved | "The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in doses of 18 mg in July 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| Jul 2024 | [AUSTEDO (deutetrabenazine) FDA approval](https://sec-api.dev/pdufa/deutetrabenazine) | TEVA |  | completed, approved | "In July 2024, the FDA approved the 18 mg dosage for AUSTEDO XR, making it a one pill, once-daily option for all available doses." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/exh_991.htm)) |
| October 22, 2024 | [SELARSDI (selarsdi) FDA approval](https://sec-api.dev/pdufa/selarsdi) | TEVA |  | completed, approved | "On October 22, 2024, the FDA approved SELARSDI in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion, expanding its label to include the treatment of adults with Crohn's disease and ulcerative colitis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| January 29, 2025 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/exh_991.htm)) |
| May 7, 2025 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325002849/exh_991.htm)) |
| July 30, 2025 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325004808/exh_991.htm)) |
| July 30, 2025 | [Degevma (denosumab-adet) complete response letter (CRL)](https://sec-api.dev/pdufa/denosumab-adet) | TEVA |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761385_20250730.pdf%22)) |
| Aug 2025 | [AJOVY® (fremanezumab) FDA approval](https://sec-api.dev/pdufa/fremanezumab) | TEVA |  | completed, approved | "AJOVY was launched in the U.S. in 2018 for the preventive treatment of migraine in adults, and in August 2025, the FDA approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6 to 17 years." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| August 5, 2025 | [Ajovy (fremanezumab-vfrm) label expansion decision](https://sec-api.dev/pdufa/fremanezumab-vfrm) | TEVA |  | completed, approved | "BLA761089 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20250805, review_priority PRIORITY; sponsor_name TEVA PHARMS USA; product AJOVY (FREMANEZUMAB-VFRM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761089%22)) |
| August 15, 2025 | [AJOVY® (fremanezumab) primary completion](https://sec-api.dev/pdufa/fremanezumab) | TEVA | Migraine | completed | "NCT04530110 (A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-15 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530110)) |
| September 18, 2025 | [BENDEKA (bendamustine) NDA/BLA submission](https://sec-api.dev/pdufa/bendamustine) | TEVA |  | completed | "Similarly, on September 18, 2025, Teva and Eagle filed suit against Almaject, Inc. and Alvogen, Inc. in the District of Delaware following the filing of another 505(b)(2) NDA for a generic BENDEKA product." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| Q4 2025 | [WELTRUZATM (olanzapine) NDA/BLA submission](https://sec-api.dev/pdufa/olanzapine) | TEVA |  | scheduled | "For olanzapine LAI, we presented new long-term safety data from the SOLARIS Trial with no PDSS observed and anticipate filing its New Drug Application (NDA) in Q4 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325007000/exh_991.htm)) |
| Oct 2025 | [Duvakitug trial start](https://sec-api.dev/pdufa/duvakitug) | TEVA |  | completed | "In October 2025, Sanofi and Teva initiated Phase 3 studies for duvakitug for Crohn's disease and ulcerative colitis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| October 7, 2025 | [Tapinarof cream, 1% primary completion](https://sec-api.dev/pdufa/tapinarof-cream-1) | TEVA | Plaque Type Psorisis | completed | "NCT06742957 (Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-07 (ACTUAL); Lead Sponsor Teva Pharmaceuticals USA." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06742957)) |
| October 10, 2025 | [UZEDY (risperidone) FDA approval](https://sec-api.dev/pdufa/risperidone) | TEVA |  | completed, approved | "On October 10, 2025, it was announced that the FDA approved UZEDY as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar 1 disorder (BD-1) in adults." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| October 10, 2025 | [UZEDY (risperidone) label expansion decision](https://sec-api.dev/pdufa/risperidone) | TEVA |  | completed, approved | "NDA213586 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20251010, review_priority STANDARD; sponsor_name TEVA; product UZEDY (RISPERIDONE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213586%22)) |
| November 5, 2025 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325007000/exh_991.htm)) |
| December 9, 2025 | [WELTRUZATM (olanzapine) NDA/BLA submission](https://sec-api.dev/pdufa/olanzapine) | TEVA |  | completed | "On December 9, 2025, Teva submitted a New Drug Application ("NDA") to the FDA for olanzapine LAI (TEV-'749), based on the results from the Phase 3 trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| January 5, 2026 | [Tev-48574 dose regimen a primary completion](https://sec-api.dev/pdufa/tev-48574-dose-regimen-a) | TEVA | Crohn Disease; Colitis, Ulcerative | completed | "NCT05668013 (A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-05 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05668013)) |
| January 28, 2026 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326000462/exh_991.htm)) |
| Feb 2026 | [WELTRUZATM (olanzapine) NDA/BLA acceptance](https://sec-api.dev/pdufa/olanzapine) | TEVA |  | completed | "olanzapine LAI New Drug Application (NDA) accepted by the FDA in February 2026 for once-monthly treatment of schizophrenia in adults; preparing for the launch of olanzapine LAI in Q4 2026, subject to regulatory approval." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/exh_991.htm)) |
| March 27, 2026 | [Degevma (denosumab-adet) FDA approval](https://sec-api.dev/pdufa/denosumab-adet) | TEVA |  | completed, approved | "BLA761385 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260327, review_priority STANDARD; sponsor_name TEVA PHARMACEUTICALS, INC.; product PONLIMSI (DENOSUMAB-ADET)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761385%22)) |
| April 29, 2026 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, April 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/exh_991.htm)) |
| July 24, 2026 | [AJOVY® (fremanezumab) topline data readout](https://sec-api.dev/pdufa/fremanezumab) | TEVA | Migraine | completed | "NCT04530110 (A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-15 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530110?tab=results)) |
| July 29, 2026 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm)) |
| September 2, 2026 | [TEVA PHARMACEUTICAL INDUSTRIES LTD topline data readout](https://sec-api.dev/companies/teva/catalysts) | TEVA | Celiac disease | completed, positive | "On September 2, 2026, Teva announced positive topline results from an ongoing Phase 2a study of TEV-'408, in adults with Celiac disease." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/818686/000081868626000006/teva-20260930.htm)) |
| September 25, 2026 | [Degevma (denosumab-adet) FDA approval](https://sec-api.dev/pdufa/denosumab-adet) | TEVA |  | completed, approved | "BLA761481 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260925, review_priority STANDARD; sponsor_name TEVA PHARMACEUTICALS, INC.; product DEGEVMA (DENOSUMAB-ADET)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761481%22)) |
| September 28, 2026 | [Prolia® (denosumab) FDA approval](https://sec-api.dev/pdufa/denosumab) | TEVA |  | completed, approved | "On September 28, 2026, we announced that the FDA approved DEGEVMA (denosumab-adet) as a biosimilar to Xgeva® (denosumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm)) |
| Q4 2026 | [WELTRUZATM (olanzapine) trial start](https://sec-api.dev/pdufa/olanzapine) | TEVA |  | scheduled | "TEV-'408 (anti-IL-15): encouraging Phase 1b results in vitiligo for this Teva-discovered antibody designed for quarterly subcutaneous dosing; initiation of a Phase 2 study expected in Q4 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm)) |
| October 2, 2026 | [Tev-53408 dose a primary completion](https://sec-api.dev/pdufa/tev-53408) | TEVA | Celiac Disease | completed | "NCT06807463 (A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-02 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807463)) |
| Oct 2026 to Jan 2027 | [Tev-53408 dose a topline data readout](https://sec-api.dev/pdufa/tev-53408) | TEVA | Celiac Disease | scheduled | "NCT06807463 (A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-02 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807463)) |
| October 8, 2026 | [WELTRUZATM (olanzapine) FDA approval](https://sec-api.dev/pdufa/olanzapine) | TEVA | schizophrenia in adults | completed, approved | "NDA219007 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20261008, review_priority STANDARD; sponsor_name TEVA; product WELTRUZA (OLANZAPINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219007%22)) |
| October 26, 2026 | [Fp/abs primary completion](https://sec-api.dev/pdufa/fp-abs) | TEVA | Asthma | completed | "NCT06664619 (A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06664619)) |
| Oct 2026 to Jan 2027 | [Fp/abs topline data readout](https://sec-api.dev/pdufa/fp-abs) | TEVA | Asthma | scheduled | "NCT06664619 (A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06664619)) |
| November 3, 2026 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm)) |
| November 3, 2026 | [WELTRUZA (weltruza) FDA approval](https://sec-api.dev/pdufa/weltruza) | TEVA |  | completed, approved | "The FDA approval of WELTRUZA has further advanced our innovative portfolio, our recently announced biosimilars agreement with Samsung Bioepis has strengthened our generics powerhouse and our return to investment grade reflects the transformation of our financial position." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm)) |
| Dec 2026 to Mar 2027 | [TEV-56248 topline data readout](https://sec-api.dev/pdufa/tev-56248) | TEVA | Asthma | scheduled | "NCT06052267 (A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06052267)) |
| December 2026 | [TEV-56248 primary completion](https://sec-api.dev/pdufa/tev-56248) | TEVA | Asthma | scheduled | "NCT06052267 (A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06052267)) |
| Q1 2027 | [Ecopipam PDUFA date](https://sec-api.dev/pdufa/ecopipam) | TEVA |  | scheduled | "The U.S. FDA accepted the ecopipam New Drug Application (NDA) for review, advancing a potential first-in-class selective D1 receptor anti-agonist for Tourette syndrome in the pediatric population, with an action date expected in Q1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm)) |
| Sep to Dec 2027 | [TEV-56286 topline data readout](https://sec-api.dev/pdufa/tev-56286) | TEVA | Multiple System Atrophy | scheduled | "NCT06568237 (A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-15 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568237)) |
| September 2027 | [TEV-56286 primary completion](https://sec-api.dev/pdufa/tev-56286) | TEVA | Multiple System Atrophy | scheduled | "NCT06568237 (A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-15 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568237)) |
| May to Aug 2029 | [Emrusolmin topline data readout](https://sec-api.dev/pdufa/emrusolmin) | TEVA | Multiple System Atrophy | scheduled | "NCT07197866 (An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-03 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07197866)) |
| May 2029 | [Emrusolmin primary completion](https://sec-api.dev/pdufa/emrusolmin) | TEVA | Multiple System Atrophy | scheduled | "NCT07197866 (An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-03 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07197866)) |
| Sep to Dec 2030 | [Tev-53408 dose a topline data readout](https://sec-api.dev/pdufa/tev-53408) | TEVA | Vitiligo | scheduled | "NCT07920211 (Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-09-12 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07920211)) |
| September 2030 | [Tev-53408 dose a primary completion](https://sec-api.dev/pdufa/tev-53408) | TEVA | Vitiligo | scheduled | "NCT07920211 (Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-09-12 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07920211)) |

## Drugs

- [Cassipa (buprenorphine hydrochloride; naloxone hydrochloride)](https://sec-api.dev/pdufa/buprenorphine-naloxone): 
- [Degevma (denosumab-adet)](https://sec-api.dev/pdufa/denosumab-adet): 
- [AUSTEDO (deutetrabenazine)](https://sec-api.dev/pdufa/deutetrabenazine): 
- [Ecopipam](https://sec-api.dev/pdufa/ecopipam): 
- [Alvaiz (eltrombopag choline)](https://sec-api.dev/pdufa/eltrombopag-choline): 
- [Emrusolmin](https://sec-api.dev/pdufa/emrusolmin): Multiple System Atrophy
- [Armonair Respiclick (fluticasone propionate)](https://sec-api.dev/pdufa/fluticasone-propionate): 
- [Airduo Digihaler (fluticasone propionate; salmeterol xinafoate)](https://sec-api.dev/pdufa/fluticasone-propionate-salmeterol-xinafoate): 
- [Fosaprepitant Dimeglumine (fosaprepitant dimeglumine)](https://sec-api.dev/pdufa/fosaprepitant-dimeglumine): 
- [Fp/abs](https://sec-api.dev/pdufa/fp-abs): Asthma
- [AJOVY® (fremanezumab)](https://sec-api.dev/pdufa/fremanezumab): Migraine
- [Ajovy (fremanezumab-vfrm)](https://sec-api.dev/pdufa/fremanezumab-vfrm): 
- [Vantrela Er (hydrocodone bitartrate)](https://sec-api.dev/pdufa/hydrocodone): 
- [WELTRUZATM (olanzapine)](https://sec-api.dev/pdufa/olanzapine): schizophrenia in adults
- [TAXOL® (paclitaxel)](https://sec-api.dev/pdufa/paclitaxel): with platinum-resistant ovarian cancer, advanced btc, severe endocrinologic, oncologic, metabolic and neurologic disorders, platinum-resistant ovarian cancer, high-impact, difficult-to-treat cancers
- [Milprosa (progesterone)](https://sec-api.dev/pdufa/progesterone): 
- [Cinqair (reslizumab)](https://sec-api.dev/pdufa/reslizumab): 
- [UZEDY (risperidone)](https://sec-api.dev/pdufa/risperidone): schizophrenia in adults
- [Romidepsin (romidepsin)](https://sec-api.dev/pdufa/romidepsin): 
- [SELARSDI (selarsdi)](https://sec-api.dev/pdufa/selarsdi): 
- [SIMLANDI® (simlandi)](https://sec-api.dev/pdufa/simlandi): 
- [Tev-48574 dose regimen a](https://sec-api.dev/pdufa/tev-48574-dose-regimen-a): Crohn Disease
- [Tev-53408 dose a](https://sec-api.dev/pdufa/tev-53408): Celiac Disease, Vitiligo
- [TEV-56248](https://sec-api.dev/pdufa/tev-56248): Asthma
- [TEV-56286](https://sec-api.dev/pdufa/tev-56286): Multiple System Atrophy
- [WELTRUZA (weltruza)](https://sec-api.dev/pdufa/weltruza): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/teva/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TEVA catalysts: TEVA PHARMACEUTICAL INDUSTRIES LTD PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/teva/catalysts

```bibtex
@misc{secapidev_companies_teva_catalysts_20261116,
  title        = {TEVA catalysts: TEVA PHARMACEUTICAL INDUSTRIES LTD PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/teva/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_teva_catalysts_20261116","title":"TEVA catalysts: TEVA PHARMACEUTICAL INDUSTRIES LTD PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/teva/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
